FGFR4 and MET

Number of citations of the paper that reports this interaction (PubMedID 28205554)
52

Data Source:
BioGRID (fluorescent resonance energy transfer)

		FGFR4	MET
Description		fibroblast growth factor receptor 4	MET proto-oncogene, receptor tyrosine kinase
Image
GO Annotations	Cellular Component	Extracellular Region Endosome Endoplasmic Reticulum Golgi Apparatus Plasma Membrane Integral Component Of Plasma Membrane Cell-cell Junction Transport Vesicle Receptor Complex	Extracellular Region Plasma Membrane Integral Component Of Plasma Membrane Basal Plasma Membrane Cell Surface Integral Component Of Membrane Receptor Complex
	Molecular Function	Transmembrane Receptor Protein Tyrosine Kinase Activity Fibroblast Growth Factor-activated Receptor Activity Protein Binding ATP Binding Heparin Binding Fibroblast Growth Factor Binding	Protein Tyrosine Kinase Activity Transmembrane Receptor Protein Tyrosine Kinase Activity Hepatocyte Growth Factor-activated Receptor Activity Protein Binding ATP Binding Semaphorin Receptor Activity Protein Phosphatase Binding Identical Protein Binding
	Biological Process	Transmembrane Receptor Protein Tyrosine Kinase Signaling Pathway Multicellular Organism Development Positive Regulation Of Cell Population Proliferation Fibroblast Growth Factor Receptor Signaling Pathway Positive Regulation Of Gene Expression Regulation Of Extracellular Matrix Disassembly Cell Migration Peptidyl-tyrosine Phosphorylation Regulation Of Lipid Metabolic Process Positive Regulation Of Kinase Activity Glucose Homeostasis Cholesterol Homeostasis Positive Regulation Of Catalytic Activity Positive Regulation Of Proteolysis Protein Autophosphorylation Phosphate Ion Homeostasis Positive Regulation Of ERK1 And ERK2 Cascade Regulation Of Bile Acid Biosynthetic Process Response To Bile Acid Positive Regulation Of DNA Biosynthetic Process	Endothelial Cell Morphogenesis Liver Development Phagocytosis Signal Transduction Cell Surface Receptor Signaling Pathway Transmembrane Receptor Protein Tyrosine Kinase Signaling Pathway Multicellular Organism Development Nervous System Development Negative Regulation Of Autophagy Cell Migration Peptidyl-tyrosine Phosphorylation Neuron Differentiation Pancreas Development Positive Regulation Of Microtubule Polymerization Positive Regulation Of Kinase Activity Negative Regulation Of Rho Protein Signal Transduction Positive Regulation Of Transcription By RNA Polymerase II Hepatocyte Growth Factor Receptor Signaling Pathway Branching Morphogenesis Of An Epithelial Tube Positive Chemotaxis Negative Regulation Of Stress Fiber Assembly Positive Regulation Of Protein Kinase B Signaling Establishment Of Skin Barrier Negative Regulation Of Thrombin-activated Receptor Signaling Pathway Semaphorin-plexin Signaling Pathway Negative Regulation Of Hydrogen Peroxide-mediated Programmed Cell Death Negative Regulation Of Guanyl-nucleotide Exchange Factor Activity Positive Regulation Of Endothelial Cell Chemotaxis
Pathways		PI3K Cascade PIP3 activates AKT signaling betaKlotho-mediated ligand binding FGFR4 mutant receptor activation FGFR4 ligand binding and activation Constitutive Signaling by Aberrant PI3K in Cancer Phospholipase C-mediated cascade; FGFR4 FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 PI-3K cascade:FGFR4 Negative regulation of FGFR4 signaling Signaling by FGFR4 in disease RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer Sema4D mediated inhibition of cell attachment and migration RAF/MAP kinase cascade MET Receptor Activation Negative regulation of MET activity PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates RAS signaling MET activates PI3K/AKT signaling MET activates PTPN11 MET activates PTK2 signaling InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell MET interacts with TNS proteins MET activates RAP1 and RAC1 MET receptor recycling MET activates STAT3 MECP2 regulates neuronal receptors and channels
Drugs		Heparin Ponatinib Lenvatinib Erdafitinib Pemigatinib	K-252a SGX-523 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide 2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol AMG-208 1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE Crizotinib Cabozantinib Capmatinib Fostamatinib Tivantinib Brigatinib Amuvatinib
Diseases
GWAS		Activated partial thromboplastin time ( 22703881) Apolipoprotein A1 levels ( 32203549) Body fat distribution (arm fat ratio) ( 30664634) Body fat distribution (trunk fat ratio) ( 30664634) Body shape index ( 34021172) Circulating fibroblast growth factor 23 levels ( 30217807) Height ( 28552196 25282103 31562340) Hemoglobin levels ( 32327693) Hip circumference adjusted for BMI ( 34021172) Hip index ( 34021172) Hip shape (DXA scan) ( 30320955) Narrowest width of the femoral neck ( 30888730) Nonsyndromic cleft lip ( 31609978) Type 2 diabetes ( 32499647 30718926) Waist circumference adjusted for BMI (adjusted for smoking behaviour) ( 28443625) Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction) ( 28448500) Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction) ( 28443625) Waist circumference adjusted for BMI in active individuals ( 28448500) Waist circumference adjusted for BMI in non-smokers ( 28443625) Waist circumference adjusted for BMI in smokers ( 28443625) Waist circumference adjusted for body mass index ( 34021172 25673412 28448500) Waist-hip index ( 34021172) Waist-to-hip ratio adjusted for BMI ( 34021172 26426971) Waist-to-hip ratio adjusted for BMI (additive genetic model) ( 30778226) Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour) ( 28443625) Waist-to-hip ratio adjusted for BMI (age <50) ( 26426971) Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction) ( 28443625) Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test) ( 26426971) Waist-to-hip ratio adjusted for body mass index ( 26785701 25673412)	Age at first sexual intercourse ( 34211149) Alanine aminotransferase levels ( 33547301) Blood protein levels ( 30072576) Gamma glutamyl transferase levels ( 29403010 33339817) HDL cholesterol levels ( 28334899) Hematocrit ( 28017375) Lung function (FEV1/FVC) ( 30804560) Medication use (beta blocking agents) ( 31015401) Multiple sclerosis (severity) ( 19010793) PR segment duration ( 24850809) Pulse pressure ( 30578418) Resting heart rate ( 29769521 27798624) Triglyceride levels ( 28334899) Triglycerides ( 24097068) Waist-to-hip ratio adjusted for BMI ( 26426971) Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test) ( 26426971)
Interacting Genes		85 interacting genes: ABCB5 AKT1 ANGPTL4 ARAF ARNT BECN1 BLID CASC3 CBLC CCND2 CCNE1 CD44 CDH2 CDK4 CDK6 CDKN2A CDKN2B CDKN2C DIRAS3 EPHA2 EPHA4 EPSTI1 ERBB2 ERRFI1 FGF1 FGF17 FGF18 FGF19 FGF2 FGF3 FGF4 FGF5 FGF6 FGF7 FGF8 FGF9 FZR1 GLCE GLIS2 GRM1 HGF HIF1A IFT80 IGF1R KDELR2 LATS2 LRATD2 MAP2K5 MAP2K6 MAP3K5 MAPK14 MDM4 MET MSH2 MTA3 MYC NF2 NSD3 OSGIN1 PDGFRA PDLIM2 PLCG1 PPP3CA PSMC3IP PTPN11 PTPN12 PTPN6 PTPRR RAF1 RASL10B RASSF1 RNF20 ROS1 SCGB3A1 STAT1 STAT3 STC2 STK11 TEAD2 TERT THRSP TP53 TSC1 TTYH2 WIF1	124 interacting genes: ABL2 BAG1 BCAR3 BLK BTK CAMSAP3 CASP3 CAV1 CBL CCND2 CD44 CDK4 CDK6 CDKN2B CNR1 CRK CTNNB1 CTTN DAPK3 DCN DNAJA3 EGFR EPHA2 ERBB2 FAS FES FGFR4 FGR FOXA3 FZR1 GAB1 GLIS2 GLMN GRB14 GRB2 GRB7 HCK HGF HGS HSH2D INPP5D INPPL1 ITGB1 ITGB4 ITK KCND2 KDELR2 KLK2 LATS2 LCK LYN MAP2K3 MAP2K5 MATK MRPL17 MUC20 MYC NCK1 NCK2 NF2 PABPC1 PCBD2 PIK3R1 PIK3R2 PIK3R3 PLCG1 PLCG2 PLXNB1 PTK6 PTPN11 PTPRB PTPRJ RAF1 RANBP10 RANBP9 RASA1 RASSF1 RASSF7 SH2B1 SH2B2 SH2B3 SH2D1A SH2D1B SH2D2A SH2D3C SH3BP2 SH3KBP1 SHB SHC1 SHC2 SHC3 SHC4 SHD SLA2 SLC26A3 SLC26A4 SMC1A SNAPIN SND1-IT1 SNX2 SOCS1 SOCS2 SOCS3 SOCS5 SOCS6 SPSB1 SRC STAP1 STAT3 STK11 SYK TEC TERT TNS1 TNS2 TNS3 TNS4 TP53 TXK VAV1 VAV2 VAV3 YES1 ZAP70
Entrez ID		2264	4233
HPRD ID		00625	01280
Ensembl ID		ENSG00000160867	ENSG00000105976
Uniprot IDs		B4DVP5 J3KPQ0 P22455	A0A024R728 A0A024R759 B4DLF5 E6Y365 P08581
PDB IDs		1QCT 4QQ5 4QQC 4QQJ 4QQT 4QRC 4R6V 4TYE 4TYG 4TYI 4TYJ 4UXQ 4XCU 5JKG 5NUD 5NWZ 5XFF 5XFJ 6IUO 6IUP 6J6Y 6JPE 6JPJ 6NVG 6NVH 6NVI 6NVJ 6NVK 6V9C 6YI8	1FYR 1R0P 1R1W 1SHY 1SSL 1UX3 2G15 2RFN 2RFS 2UZX 2UZY 2WD1 2WGJ 2WKM 3A4P 3BUX 3C1X 3CCN 3CD8 3CE3 3CTH 3CTJ 3DKC 3DKF 3DKG 3EFJ 3EFK 3F66 3F82 3I5N 3L8V 3LQ8 3Q6U 3Q6W 3QTI 3R7O 3RHK 3U6H 3U6I 3VW8 3ZBX 3ZC5 3ZCL 3ZXZ 3ZZE 4AOI 4AP7 4DEG 4DEH 4DEI 4EEV 4GG5 4GG7 4IWD 4K3J 4KNB 4MXC 4O3T 4O3U 4R1V 4R1Y 4XMO 4XYF 5DG5 5EOB 5EYC 5EYD 5HLW 5HNI 5HO6 5HOA 5HOR 5HTI 5LSP 5T3Q 5UAB 5UAD 5YA5 6GCU 6I04 6SD9 6SDC 6SDD 6SDE 6UBW 7B3Q 7B3T 7B3V 7B3W 7B3Z 7B40 7B41 7B42 7B43 7B44
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?